Open Access Open Badges Research article

Burden of carbapenem-resistant organisms in the Frankfurt/Main Metropolitan Area in Germany 2012/2013 – first results and experiences after the introduction of legally mandated reporting

Niels Kleinkauf1*, Angelika Hausemann1, Volkhard AJ Kempf2, René Gottschalk1 and Ursel Heudorf1

Author Affiliations

1 Public Health Authority of Frankfurt/Main, Breite Gasse 28, D- 60313 Frankfurt, Germany

2 University Hospital, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany

For all author emails, please log on.

BMC Infectious Diseases 2014, 14:446  doi:10.1186/1471-2334-14-446

Published: 19 August 2014



The federal state of Hesse, Germany, introduced a laboratory-based reporting scheme for carbapenem-resistant organisms (CROs).


The results of the first year of mandated reporting of CROs from April 2012 through March 2013 to the Public Health Authority of Frankfurt/Main, responsible for a population of 700,000 inhabitants, are described.


Within a period of 12 months 243 CROs were notified to the health authority. Of these 213 isolates had been reported from 16 of the 17 hospitals in Frankfurt/Main, 6 from ambulatory settings and 24 from clinics outside of Frankfurt/Main. Mean incidence rate per 1,000 patient days in hospitals was 0.138 (range 0.02-0.28).


In Frankfurt/Main almost all hospitals have reported CROs in the study period though the frequency of isolation varies strongly and many facilities only report CROs sporadically. Molecular data indicate a high diversity of different carbapenemases. Autochthonous transmission must be assumed despite the absence of major outbreaks. Rapid and coordinated efforts by clinicians and health departments are crucial to control the spread of CRO infections. The mandatory reporting scheme provides important data to guide the implementation of preventive measures.

Gram-negative bacteria; Multidrug resistance; Carbapenemase; Mandatory reporting; Epidemiology; Population-based surveillance